STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
Investors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent.
<p>Investors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent.</p>